

**TITLE:** Suboxone versus Methadone for the Treatment of Opioid Dependence: A Review of the Clinical and Cost-effectiveness

**DATE:** 14 November 2013

## **CONTEXT AND POLICY ISSUES**

Addiction to opioids causes major medical, social, and economic problems to both the individual and society. Opioid dependence is defined as a strong desire to use the substance, difficulty in controlling its use, the presence of a physiological withdrawal state, tolerance of the use of the drug, neglect of alternative pleasures and interests and persistent use of the drug, despite harm to oneself and others.<sup>1</sup> It is a complex disease involving physiological, psychological, genetic, behavioral and environmental factors.<sup>2</sup> In Canada, it is estimated that there were more than 80,000 regular illegal opioid users in 2003.<sup>3</sup> The number of illegal drug-related overdose deaths in Canada was 958 in 2002.<sup>3</sup> Opioid dependence is related to the abuse of not only illegal opioid drugs (e.g. heroin), but also some of the most commonly prescription drugs, such as codeine-containing Tylenol, hydromorphone, oxycodone, morphine and others.<sup>4</sup>

Treatment of opioid dependence includes three approaches: stabilization, detoxification and maintenance.<sup>5</sup> Stabilization is usually achieved by opioid substitution treatments to ensure that the drug use becomes independent of mental state (such as craving and mood) and independent of circumstances (such as finance and physical location). The next stage is detoxification that is to withdraw from opioids. The final step is maintenance to prevent relapse.<sup>5</sup> Detoxification refers to the process by which the effects of opioid drugs are eliminated in a safe and effective manner, such that withdrawal symptoms are minimized.<sup>1</sup> Appropriate use of the detoxification agents plays a crucial role in increasing the successful detoxification rate, while minimizing the side effects and withdrawal symptoms.<sup>1</sup> Methadone ( $\mu$ -opioid receptor agonist) or buprenorphine ( $\mu$ -opioid receptor agonist and  $\kappa$ -opioid receptor antagonist) are recommended first-line treatments in opioid detoxification.<sup>1,6</sup> Naloxone is an opioid antagonist without agonist properties. In opioid-dependent patients, naloxone precipitates withdrawal.

Suboxone (buprenorphine/naloxone) was approved by Health Canada in 2007 for substitution treatment in opioid drug dependence in adults.<sup>7</sup> It is a fixed combination of buprenorphine (a partial  $\mu$ -opioid receptor agonist) with naloxone (an opioid antagonist) in a 4:1 ratio.<sup>8</sup> The addition of naloxone to buprenorphine is expected to decrease the intravenous abuse of

**Disclaimer:** The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

**Copyright:** This report contains CADTH copyright material and may contain material in which a third party owns copyright. **This report may be used for the purposes of research or private study only.** It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

**Links:** This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

buprenorphine, because when taken sublingually, absorption of naloxone is minimal, however it can rapidly precipitate opioid withdrawal when injected.<sup>9,10</sup> Suboxone is recommended for the treatment of opioid dependence for patients in whom methadone is contraindicated (such as patients at high risk of, or with QT prolongation, or hypersensitivity to methadone).<sup>11</sup>

The purpose of this review is to provide evidence on the comparative clinical effectiveness and cost-effectiveness of use of Suboxone compared with methadone, for the treatment of patients with opioid dependence. Subgroups such as children and pregnant women may also have access to opioids thus, the clinical benefits and risks of Suboxone for these patients will be examined as well, when evidence is available.

## **RESEARCH QUESTIONS**

1. What is the comparative clinical effectiveness of Suboxone compared with methadone for the treatment of patients with opioid dependence?
2. What is the cost-effectiveness of Suboxone compared with methadone for the treatment of patients with opioid dependence?

## **KEY FINDINGS**

Limited evidence suggests that Suboxone may have similar clinical effects as methadone on retention in treatment and heroin use among adult patients with opioid dependence, and may be more cost-effective than methadone. There was no evidence of the comparative effectiveness of Suboxone versus methadone in other subgroups. Cost-effectiveness of Suboxone in a Canadian population is uncertain.

## **METHODS**

### **Literature Search Strategy**

A limited literature search was conducted on key resources including Ovid MEDLINE, Ovid Embase, PubMed, The Cochrane Library (2013, Issue 10), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit retrieval by publication type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2003 and October 15, 2013.

### **Selection Criteria and Methods**

One reviewer screened citations to identify publications that met the inclusion criteria. Potentially relevant articles were retrieved based on the review of titles and abstracts. Full-text articles were considered for inclusion based on the selection criteria listed in Table 1. Rapid Response reports are organized so that the evidence for each research question is presented separately.

**Table 1: Selection Criteria**

<b>Population</b>	Patients of any age with opioid dependence
<b>Intervention</b>	Suboxone (buprenorphine / naloxone)
<b>Comparator</b>	Methadone or Methadose (a commercial methadone product)
<b>Outcomes</b>	Clinical efficacy (e.g. use of opioid including heroin and other drugs of abuse, retention in treatment, harms reduction, health-related quality of life, and safety), Cost-effectiveness
<b>Study Designs</b>	Health technology assessment (HTA), systematic review (SR) and meta-analysis (MA), randomized controlled trial (RCT), non-randomized study, and economic evaluation

**Exclusion Criteria**

Studies were excluded if they did not satisfy the selection criteria in Table 1, or were full text articles published prior to January 2003. Health technology assessments, meta-analyses, and systematic reviews were excluded if there was incomplete reporting of methods or if they were superseded by a more recent or more rigorous review. Studies that were deemed to have incomplete reporting of outcomes, such as not reporting numerical values for outcomes, were excluded. Economic evaluations were excluded if they were not cost-effectiveness or cost-utility analyses.

**Critical Appraisal of Individual Studies**

Critical appraisal of a study was conducted based on an assessment tool appropriate for the particular study design. The Downs and Black checklist<sup>12</sup> was used for RCTs and non-randomized studies. The economic evaluations were assessed using the 35-item Drummond’s checklist.<sup>13,14</sup> A numeric score was not calculated for each study. Instead, the strengths and limitations of each study were summarized and described.

**SUMMARY OF EVIDENCE**

**Quantity of Research Available**

One hundred and twenty-one articles were identified from the literature search. Upon screening titles and abstracts, 28 potentially relevant articles were selected for full-text review. Of these, 19 did not satisfy the inclusion criteria and were excluded. The nine included reports of eight unique clinical studies and comprised four RCTs (a secondary analysis on data from one RCT was performed), two non-RCTs and two economic evaluations. No relevant health technology assessments, systematic reviews or meta-analyses were identified. The selection process is described in Appendix 1.

**Summary of Study Characteristics**

Characteristics of the included clinical trials and economic evaluations are summarized below and details are provided in Appendix 2.

### *Clinical Effectiveness*

In the included RCTs and non-randomized trials, the baseline patient characteristics such as demographics, drug history, treatment history were similar between two treatment groups.

#### Randomized-controlled trials

Four relevant RCTs comparing Suboxone with methadone were identified.<sup>15-18</sup> Three RCTs<sup>15,17,18</sup> were published from the US, and one<sup>16</sup> was published in 2012 from Georgia. The number of recruited patients in these studies ranged between 54 to 1,269. Drugs being misused included heroin, cocaine, cannabis, amphetamines and other prescription opioids. The mean duration of drug use ranged from 20 days to 12 years. Treatment durations in these trials ranged between three to six months. All RCTs reported retention in treatment and use of opioids at study end (assessed by self-report or urine test). Safety data were reported in all but one RCT.<sup>15</sup> One American study<sup>17</sup> evaluated the effects of Suboxone or methadone on liver health, and indicated that results on drug use will be analyzed in a future paper. In addition, secondary analysis on data from this RCT was performed and the results were published in a different journal.<sup>19</sup> Two patients from the original RCT were excluded from the analysis due to pregnancy and change in treatment plan during the study.

#### Non-randomized-controlled trials

Two prospective cohort studies comparing Suboxone with methadone in adult patients were identified.<sup>20,21</sup> One<sup>20</sup> was published in 2013 from the UK, and another one<sup>21</sup> was published in 2007 from Finland. The number of patients enrolled in these non-RCTs ranged from 33 to 71. These studies reported on days of opioid use and change in cognitive performance (attention, working memory and verbal memory) after the treatment with Suboxone or methadone.

### *Cost-Effectiveness*

A recent economic evaluation was conducted in Greece, to evaluate the cost-effectiveness of opioid substitution treatment (mainly methadone and buprenorphine) in this country.<sup>22</sup> The investigated study drugs were methadone and buprenorphine monotherapy, and Suboxone. The data used were retrospectively retrieved from the local health authority databases. The expenses included personnel, drugs/consumables, medical consultations/diagnostic investigations, maintenance of equipment and buildings, and overheads. No discount rates were applied. Prices (in Euros) were those of the Greek National Health System in 2008. The clinical effectiveness was assessed using the completion of treatment and the number of deaths that were related to the use and/or overdose of illicit opioid drugs.

An economic evaluation by Doran et al.<sup>23</sup> was performed in Australia to examine the cost-effectiveness of high-dose buprenorphine, Suboxone, low-dose buprenorphine, and methadone. A treatment provider perspective was adopted with a reference year of 1998 to 1999. Resources use was identified at both the patient and facility level, which included staff time, diagnostics, medications, supplies, equipment, and ancillary services. The summation of patient and facility resource use provided an estimate of total cost of each patient's treatment episode. Three economic models were examined: comparison of methadone with low dose buprenorphine, comparison of methadone with high dose buprenorphine, and comparison of methadone with Suboxone. The third model is relevant to our review. The primary measure of

clinical effectiveness was the change in number of heroin-free days between the month prior to treatment and the 6<sup>th</sup> month.

### Summary of Critical Appraisal

The strengths and limitations of the included studies are summarized in Appendix 3.

#### Randomized controlled trials

All four RCTs<sup>15-18</sup> clearly stated the objective and the selection criteria and described patient characteristics, interventions and outcomes. One RCT was a double-blind, double-dummy RCT and described the methods of blinding clearly.<sup>18</sup> Two stated that they had an open-label design.<sup>15,17</sup> For one RCT, it was unclear whether it was a blinded trial.<sup>16</sup> A sample size calculation was reported in one RCT.<sup>18</sup> In the largest RCT enrolling 1269 patients,<sup>17</sup> the authors indicated that the US Food and Drug Administration required a minimum of 300 evaluable participants on each medication, hence a power calculation was not performed. No power calculation was reported for the other two RCTs.<sup>15,16</sup> All of the four RCTs reported results for patients who had completed the study or had evaluable data. Intention-to-treat analysis was not specified in any of these trials. The proportion of patients who completed the study was generally low. One RCT, conducted in Georgia,<sup>16</sup> reported a completion rate of higher than 80% in the randomized population. In the other three RCTs, the completion rates ranged between 20% to lower than 50% in the overall population. The dropout rates were comparable between treatment groups, except for the Saxon study (more patients with Suboxone dropped out the study than those with methadone, 54% versus 26%, respectively). Generalizability was limited as it was uncertain as to whether the study patients were representative of all patients.

#### Non-randomized-controlled trials

Both of the non-randomized studies<sup>20,21</sup> were prospective studies. However, it was unclear if the outcome assessors or patients were blinded to the treatment. Patient characteristics were described in one study. Both studies described the interventions and outcomes. Both studies provided P-values though not always for all outcomes. Generalizability was uncertain as to whether the study patients were representative of all patients. Both studies had small sample size.

#### Economic evaluations

The economic evaluation reports<sup>22,23</sup> were considered to be of high methodological quality according to the Drummond checklist. The research question was well defined and the analysis method was clearly stated. The key parameters on which the analysis was based were justified and the time horizons were clearly specified. Sensitivity analyses were performed in both reports. One limitation of the Australian report was that the investigators based their analyses on retrospective data (cost and efficacy data) collected almost 10 years ago. In addition, the discount rate was not reported in this analysis. The generalizability of the study results to Canadian setting is uncertain due to the relatively old data. The long-term cost-effectiveness of the selected treatments is unclear since the time horizon in both economic evaluations was relatively short (six months to one year).

## Summary of Findings

The overall findings are summarized below and detailed findings from the individual clinical studies are provided in Appendix 4.

### What is the comparative clinical effectiveness of Suboxone compared with methadone for the treatment of patients with opioid dependence?

#### *Opioid use*

##### Randomized-controlled trials

In one RCT including 54 patients,<sup>15</sup> clinical outcomes were reported for patients who completed the six month treatment with Suboxone or methadone. In 26 patients (48.1%, 13 in each group) who remained in the study, five patients in the Suboxone group compared with 0 from the methadone group reported illicit opioid use ( $P = 0.039$ ). The between-group difference in positive urine test for opioid use was not found to be statistically significant (five patients in the Suboxone group compared with 2 in the methadone group,  $P > 0.05$ ).

In the double-blind RCT by Kamien et al.,<sup>18</sup> patients in the combined Suboxone groups (low dose and high dose groups combined) reported numerically fewer days of heroin use in the past 30 days, when compared with combined methadone groups,  $P = 0.05$ . Higher doses of Suboxone or methadone were associated with larger reduction in days of heroin use, compared with lower doses Suboxone or methadone; however, statistical tests of differences in days of heroin use between Suboxone and methadone in respective high- or low-dose group were not performed.

##### Non-randomized-controlled trials

One non-RCT<sup>20</sup> in patients who had already received 6 months treatment with Suboxone or methadone at study entry found that significantly more Suboxone-treated patients reported “abstinent from heroin use in the past 90 days” compared with those treated with methadone (71.4% versus 37.7%). “Days of heroin use in the past 90 days” were similar at 6-months, however those in the Suboxone group reported significantly fewer days of heroin use after 14 months of treatment, compared with the methadone group (Suboxone: reduced from 38.64 days to 8.5 days; methadone: reduced from 37.40 days to 24.15 days). In terms of “treatment motivation”, significantly more patients with methadone viewed their drug use as a problem and indicated their intention to adhere to treatment. Attrition from 8-month assessment was similar between methadone and Suboxone.

#### *Retention in treatment*

##### Randomized-controlled trials

In the Neumann study,<sup>15</sup> there was no significant difference in the numbers of patients who had completed the treatment of SUB or MET, 13 patients in each group.

In the Saxon study,<sup>17</sup> patients in the Suboxone group completed fewer weeks of treatment (mean 18.5 weeks) as compared to those in the methadone group (mean 25.8 weeks),  $P < 0.0001$ . In the secondary analysis using data from this RCT,<sup>19</sup> significantly fewer Suboxone patients (46%) than methadone patients (74%) completed treatment at 24 weeks,  $P < 0.01$ .

Kamien and coworkers reported similar retention time between Suboxone and methadone: 12.1 weeks, 13.2 weeks, 12.5 weeks and 12.3 weeks for patients in low dose Suboxone, high dose Suboxone, low dose methadone and high dose methadone groups, respectively.<sup>18</sup> The between-group differences in retention time were not statistically significant.

### Non-randomized-controlled trials

In the non-RCT by McKeganey,<sup>20</sup> there were no statistically significant differences in rates of attrition from the 8-month follow-up assessment (rates of attending: 67.9% for Suboxone versus 62.3% for methadone,  $P > 0.05$ ).

### *Patient perceptions toward disease and treatment*

In the non-RCT by McKeganey,<sup>20</sup> at study entry (after six months treatment with Suboxone or methadone), significantly higher scores of the Texas Christian University Self-Rating Form (TUC/SRF) were reported in patients treated with methadone than those with Suboxone, indicating that they were more likely to view their drug use as a problem and show readiness for adherence to treatment.

### *Cognitive performance*

One non-RCT evaluated the effects of Suboxone or methadone on patient's cognitive abilities using specific tests.<sup>21</sup> Results showed that Suboxone was superior to methadone in attention testing. Similar test results were observed in the Suboxone group and the methadone group for working memory and verbal memory.

### *Safety*

### Randomized-controlled trials

The Neumann study reported similar rates of self-reported adverse effects between the Suboxone group and the methadone group, eight patients (61.5%) versus nine patients (69.2%), respectively.<sup>15</sup> However, no further descriptions on adverse events were provided.

Significantly more adverse events were reported in the Suboxone group than the methadone group in a Georgia study,<sup>16</sup> 108 events versus 80 events, respectively,  $P = 0.003$ . The most commonly reported events in both groups were insomnia, constipation and depression, but were mild to moderate in intensity. There were no reports of deaths, overdoses, suicide attempts or other serious adverse events.

In one RCT which focused on liver health,<sup>17</sup> rates of serious adverse events (SAEs) were not significantly different between treatment groups, 38 patients (5.2%) in the Suboxone group versus 45 (8.7%) in the methadone group. The SAEs reported for Suboxone included persistent

headache, non-cardiac chest pain, spontaneous abortion, suicidal ideation, suicidal threat, cholecystitis, accidental benzodiazepine overdose, and suicide plan by heroin overdose; while SAEs observed for methadone included alprazolam overdose, drug intoxication requiring hospitalization, hospitalization for vomiting, bradycardia, change in metal status, inadvertent methadone overdose, gastric ulcer, and one death from accidental acute combined use of cocaine and methadone.

In the Kamien study,<sup>18</sup> SAEs were experienced by one patient treated with Suboxone and four patients treated with methadone. There were no other safety data reported in this study.

#### Non-randomized-controlled trials

None of the non-randomized studies examined the safety of the use of Suboxone.

#### What is the cost-effectiveness of Suboxone compared with methadone for the treatment of patients with opioid dependence?

In the Greek cost-effectiveness analysis, the estimated patient total costs for one year were 2,876 euros for treatment with Suboxone, while it was 5,626 euros for treatment with methadone. In terms of the clinical effectiveness, Suboxone increased the percentage of treatment completion approximately 1.5-fold, and percentage of deaths in the Suboxone group was 2.5-fold smaller compared with that in the methadone group. As a result, the cost-effectiveness analysis demonstrated that Suboxone therapy was dominating the other two drugs, methadone and buprenorphine monotherapy. The incremental cost-effectiveness ratio (ICER) for Suboxone versus methadone was -795.03 euros with respect to “treatment completion”, and was -1,410.7 euros with respect to “percentage of avoided deaths”.

In the Australian economic evaluation, the mean treatment costs over a 6-month period were AUD\$1,593 for Suboxone, and AUD\$1,415 for methadone. The changes in the number of heroin-free days between the month prior to treatment (baseline) and the sixth month were 7.34 days for Suboxone and 6.84 days for methadone. Therefore, the ICER for the comparison between Suboxone and methadone was AUD\$357 (confidence interval: -1,520 to 2,367). The results suggested that the combination of buprenorphine and naloxone was more expensive but more effective than methadone for patients with opioid dependence. However, the between-treatment difference in cost-effectiveness was not statistically significant.

#### **Limitations**

Most of the included clinical trials had small sample size and power calculations were not described. Results from these underpowered studies should be interpreted with caution, since a difference between treatment groups may not be detected. In addition, all studies reported results from the evaluable population, or from patients who had completed the study. However, the proportions of patients that remained in the study were low. Effectiveness of Suboxone in patients who withdrew the study earlier is uncertain.

Adverse effects were insufficiently reported and not all studies reported on adverse events. Infection was reported in a number of studies but the reporting of infection varied (e.g. catheter related infection, blood stream infection, and exit site infection). Also, the studies were not powered to detect adverse events, so differences in rare event rates may not be detectable.

The studies were conducted at single centers, mainly tertiary hospitals so generalizability of the findings may be limited.

None of the clinical trials or economic evaluations was conducted in Canada, so applicability to the Canadian setting is unclear.

## **CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING**

Inconsistent results of clinical effectiveness and safety of the use of Suboxone in patients with opioid dependence were observed across the included studies of this review. Results from randomized controlled trials indicated that in adult patients, compared with methadone, treatment with Suboxone may have similar effects on retention in treatment, and heroin or other opioid use. Rates of adverse events for Suboxone were similar to methadone. The results should be interpreted with caution, due to the small sample sizes, relatively short study durations (3 to 6 months therapy), and high discontinuation rates. Data from non-randomized controlled trials suggested that Suboxone had similar effect as methadone on number of days of heroin use. In addition, compared with methadone, Suboxone did not show significant difference in cognitive performance in the study population after 6 weeks treatment.

Two economic evaluations conducted outside of Canada demonstrated the cost-effectiveness benefits related to Suboxone when comparing with methadone for opioid-dependent patients.

Opioid dependence is a chronic, relapsing illness and patients usually need long-term maintenance treatment. The limited evidence suggested that Suboxone may be an alternative in the study population. There is no evidence available on other clinically relevant outcomes, such as health-related quality of life, mortality. Also, there is a lack of evidence to evaluate the benefits/risks of Suboxone in special populations (children, pregnant women, or others). Evidence on Suboxone compared with Methadose, a commercial product of methadone, is also unavailable. There was no Canadian economic study identified to examine the cost-effectiveness of the use of Suboxone in Canadian population.

### **PREPARED BY:**

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439

[www.cadth.ca](http://www.cadth.ca)


## REFERENCES

1. National Collaborating Centre for Mental Health. Drug misuse: opioid detoxification [Internet]. London: The British Psychological Society, Royal College of Psychiatrists; 2008. (NICE clinical guideline; no. 52). [cited 2013 Nov 14]. Available from: <http://www.nice.org.uk/nicemedia/live/11813/35999/35999.pdf>
2. American Society of Addiction Medicine. Public policy statement on rapid and ultra rapid opioid detoxification [Internet]. Chevy Chase (MD): The Society; 2005. [cited 2013 Nov 14]. Available from: <http://www.asam.org/docs/public-policy-statements/1rod-urod---rev-of-oadusa-4-051.pdf?sfvrsn=0>
3. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. *Public Health*. 2006 Apr;120(4):320-8.
4. Do you know... prescription opioids [Internet]. Toronto: Centre for Addiction and Mental Health (CAMH); 2010. [cited 2013 Nov 13]. Available from: [http://www.camh.ca/en/hospital/health\\_information/a\\_z\\_mental\\_health\\_and\\_addiction\\_information/oxycontin/Pages/opioids\\_dyk.aspx](http://www.camh.ca/en/hospital/health_information/a_z_mental_health_and_addiction_information/oxycontin/Pages/opioids_dyk.aspx)
5. Praveen KT, Law F, O'Shea J, Melichar J. Opioid dependence. *Clin Evid* [Internet]. 2011 [cited 2013 Nov 14];09(1015). Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/meh/1015/1015-get.pdf>
6. Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. *World J Biol Psychiatry*. 2011 Apr;12(3):160-87.
7. e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 1997 -. Suboxone®; 2013 Jun 17 [cited 2013 Nov 14]. Available from: <http://www.e-therapeutics.ca/> Subscription required.
8. Orman JS, Keating GM. Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. *CNS Drugs*. 2009 Oct 1;23(10):899-902.
9. Soyka M. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. *Expert Opin Drug Deliv*. 2012 Nov;9(11):1409-17.
10. Orman JS, Keating GM. Buprenorphine naloxone. *Drugs*. 2009;69(5):577-607.
11. Common Drug Review. Buprenorphine/Naloxone (Suboxone - Schering-Plough Canada Inc.) [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2008 Sep 24. [cited 2013 Nov 14]. (CEDAC final recommendation). Available from: [http://www.cadth.ca/media/cdr/complete/cdr\\_complete\\_Suboxone\\_September-24-2008.pdf](http://www.cadth.ca/media/cdr/complete/cdr_complete_Suboxone_September-24-2008.pdf)
12. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* [Internet]. 1998 Jun [cited 2013 Nov

- 5];52(6):377-84. Available from:  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1756728/pdf/v052p00377.pdf>
13. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1997 May 21;277(19):1552-7.
  14. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ [Internet]. 1996 Aug 3 [cited 2013 Nov 14];313(7052):275-83. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2351717/pdf/bmj00553-0039.pdf>
  15. Neumann AM, Blondell RD, Jaanimagi U, Giambrone AK, Homish GG, Lozano JR, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32(1):68-78.
  16. Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial. Drug Alcohol Depend. 2013 Jul 31.
  17. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6.
  18. Kamien JB, Branstetter SA, Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl [Internet]. 2008 Dec [cited 2013 Nov 14];10(4):5-18. Available from: [http://www.europad.org/journal/2008/Kamien10\(4\).pdf](http://www.europad.org/journal/2008/Kamien10(4).pdf)
  19. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2013 Aug 20.
  20. McKeganey N, Russell C, Cockayne L. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. J Subst Abuse Treat. 2013 Jan;44(1):97-102.
  21. Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol [Internet]. 2007 [cited 2013 Oct 18];7. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914339/pdf/1472-6904-7-5.pdf>
  22. Geitona M, Carayanni V, Petratos P. Economic evaluation of opioid substitution treatment in Greece. Heroin Addict Relat Clin Probl [Internet]. 2012 [cited 2013 Oct 18];14(3):77-88. Available from: <http://www.europad.org/journal/2012/Geitona.pdf>

23. Doran CM. Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. *Expert Rev Pharmacoecon Outcomes Res.* 2005 Oct;5:583-91.

APPENDIX 1: Selection of Included Studies



**APPENDIX 2: Characteristics of Included Studies**

**Table A2.1: Characteristics of Included Clinical Studies**

First author, publication year, country	Study design, length of follow-up	Patient characteristics, sample size	Intervention	comparators	Main clinical outcomes
<b>RCTs</b>					
Neumann, 2013, US <sup>15</sup>	Open-label RCT Treatment duration: 6 months	Patients with chronic pain and coexistent opioid addiction to prescription opioids (not specified), duration of drug use: ~6 years  N = 54	SUB (buprenorphine 4-16 mg /naloxone 1-4 mg), average daily dose: 14.93/3.73 mg n=26	MET 10-60 mg/day, average daily dose: 29.09 mg n=28	Treatment retention, opioid use (self-report or urine test)
Otiashvili, 2013, Georgia <sup>16</sup>	RCT, blinding unknown. Treatment duration: 12 weeks Follow-up till 20 weeks.	Patients with addiction to heroin, Subutex, other opioids, stimulants, benzodiazepines and marijuana; duration of drug use: ~6 years  N = 80	SUB, mean dose 8.5 mg n = 40	MET, mean dose 39 mg n = 40	Treatment retention, opioid use (self report or urine test)
Saxon, 2013, US <sup>17</sup>  Hser, 2013, US <sup>19</sup> (secondary analysis)	Open-label RCT Treatment duration: 24 weeks Follow-up till 32 weeks	Patients with opioid dependence to injection drugs (heroin, cocaine, non-heroin opioids and amphetamines), and AST/ALT no greater than 5 times, or ALP no greater than 3 times the ULN; duration of drug use: ~20 days  N = 1269  (N = 1267 in the secondary analysis)	SUB, mean maximum daily dose 22.1 mg n = 740 (340 evaluable)	MET, mean maximum daily dose 93.2 mg n = 529 (391 evaluable)	Change in ALT and AST from baseline, treatment retention
Kamien, 2008, US <sup>18</sup>	Double-blind, double dummy RCT Treatment	Patients dependent to heroin or prescription	SUB-1: 8 mg BUP+2 mg NAL, n = 82	MET-1: 45 mg, n = 52  MET-2: 90 mg,	Opioid abstinence achieved overtime,

First author, publication year, country	Study design, length of follow-up	Patient characteristics, sample size	Intervention	comparators	Main clinical outcomes
	duration: 17 weeks N = 268	opioids; duration of drug: 9-12 years  N = 268	SUB-2: 16 mg BUP+4 mg NAL, n = 58	n = 76	retention, overall functioning
<b>Non-RCTs</b>					
McKeganey, 2013, UK <sup>20</sup>	Naturalistic comparison of MET and SUB. Patients received MET or SUB for maintenance for 6 months prior to entering the study; treatment continued and patients were followed for another 8 months	Patients with opiate dependence ≤ 12 months, and had received MET or SUB for 6 months  N=109	SUB for 14 months, mean dosage at study entry: 12.98 mg/day n=53	MET for 14 months, mean dosage at study entry: 76.29 mg/day n=56	Days of heroin use in past 90 days at study entry and 8-month follow up, % of abstinent from heroin use, perceptions toward disease and treatment (measured by TCU/SRF and SF-36)
Rapeli, 2007, Finland <sup>21</sup>	Naturalistic comparison of MET and SUB. Patients' cognitive abilities were assessed within 6 weeks after opioid substitution treatment	Patients with opioid dependence  N=50 (there was a healthy control group, n = 17)	SUB, mean dose 15.8 mg/day  n = 17	MET, mean dose 53.4 mg/day  n = 16	Attention, working memory and verbal memory (testing was done 3-6 hours after drug administration)
ALP=alkaline phosphatase; ALT=alanine amino transferase; AST=aspartate amino transferase; DAST=the Drug Abuse Screening Test; DSM-IV-TR=the Diagnostic and Statistical Manual of Mental Disorders; MET=methadone; SF-36=Short-Form Health Survey; SUB=Suboxone; TCU/SRF=Texas Christian University Self-Rating Form; UK=the United Kingdom; ULN=upper limit of normal; US=the United States of America					

**Table A2.2: Characteristics of Included Economic Evaluations**

First Author, Publication Year, Country	Study Design, Time horizon	Patient Characteristics	Intervention/ Comparators	Assumptions
Geitona, 2012, Greece <sup>22</sup>	<ul style="list-style-type: none"> <li>●cost-effectiveness analysis based on retrospective data from 2 local health authority database</li> <li>●Time horizon: 1 year</li> </ul>	Opioid users participating in OST programs in Greece	MET, BUP, SUB	The cost for SUB patients was as same as BUP patients, since they received the same clinical management
Doran, 2005, Australia <sup>23</sup>	<ul style="list-style-type: none"> <li>●cost-effectiveness analysis</li> <li>●Time horizon: 6 months</li> </ul>	Heroin dependence	MET, BUP, SUB	Each patient was provided with 8 mg of BUP on days 1 and 2 and then proceed to a dose of 16 mg BUP + 4 mg NAL for the remainder of the study period

BUP=buprenorphine; MET=methadone; NAL=naloxone; OST=opioid substitution treatment; SUB=Suboxone

**APPENDIX 3: Summary of Study Strengths and Limitations**

First Author, Publication Year, Country	Strengths	Limitations
<b>Randomized controlled trial</b>		
Neumann, 2013, US <sup>15</sup>	<ul style="list-style-type: none"> <li>• Objectives and inclusion/exclusion criteria were stated.</li> <li>• Patient characteristics, interventions, and outcomes were described.</li> <li>• Randomized but, open label study. Computerized random numbers were used for the randomization procedure. Allocation sequence was concealed from the researcher enrolling patients.</li> <li>• Number discontinued or lost to follow up were reported</li> </ul>	<ul style="list-style-type: none"> <li>• Sample size calculation was not described</li> <li>• Intent-to-treat analysis was not performed</li> <li>• Generalizability limited; uncertain as to whether study patients were representative of all patients.</li> <li>• Funding source was not declared.</li> </ul>
Otiashvili, 2013, Georgia <sup>16</sup>	<ul style="list-style-type: none"> <li>• Objectives and inclusion/exclusion criteria were stated.</li> <li>• Patient characteristics, interventions, and outcomes were described.</li> <li>• Randomized and likely open label as there was. Computerized random numbers were used for the randomization procedure.</li> <li>• Number discontinued or lost to follow up were reported</li> </ul>	<ul style="list-style-type: none"> <li>• No mention about blinding</li> <li>• Intent-to-treat analysis was not performed</li> <li>• Sample size calculations were not described</li> <li>• Generalizability limited; uncertain as to whether study patients were representative of all patients.</li> <li>• Industry-sponsored study</li> </ul>
Saxon, 2013, US <sup>17</sup>  Hser, 2013, US <sup>19</sup> (secondary analysis)	<ul style="list-style-type: none"> <li>• Objectives and inclusion/exclusion criteria were stated.</li> <li>• Patient characteristics, interventions, and outcomes were described.</li> <li>• Randomized but, open label study. For the randomization procedure, software was used.</li> <li>• Choice of sample size was justified.</li> </ul>	<ul style="list-style-type: none"> <li>• Intent-to-treat analysis was not performed</li> <li>• Generalizability limited; uncertain as to whether study patients were representative of all patients.</li> <li>• Industry-sponsored study</li> </ul>
Kamien, 2008, US <sup>18</sup>	<ul style="list-style-type: none"> <li>• Objectives and inclusion/exclusion criteria were stated.</li> <li>• Patient characteristics, interventions, and outcomes were described.</li> <li>• Double-blind randomized study. Computerized random numbers were used for the randomization</li> </ul>	<ul style="list-style-type: none"> <li>• Intent-to-treat analysis was not performed</li> <li>• Industry-sponsored study.</li> <li>• Generalizability limited; uncertain as to whether study patients were representative of all patients.</li> </ul>

First Author, Publication Year, Country	Strengths	Limitations
	<p>procedure. Allocation sequence was concealed.</p> <ul style="list-style-type: none"> <li>• Sample size calculations described</li> <li>• Number discontinued or lost to follow up were reported</li> <li>• Appeared to be intent-to-treat analysis, though not explicitly mentioned</li> <li>• P-values provided</li> </ul>	
<b>Non-randomized studies</b>		
McKeganey, 2013, UK <sup>20</sup>	<ul style="list-style-type: none"> <li>• Objectives and selection criteria were stated.</li> <li>• Patient characteristics, interventions, and outcomes were described.</li> <li>• P-values provided</li> </ul>	<ul style="list-style-type: none"> <li>• Sample size calculation was not described</li> <li>• Generalizability limited; uncertain as to whether study patients were representative of all patients.</li> <li>• Industry-sponsored study</li> </ul>
Rapeli, 2007, Finland <sup>21</sup>	<ul style="list-style-type: none"> <li>• Objectives and selection criteria were stated.</li> <li>• Patient characteristics, interventions, and outcomes were described. Interventions and outcomes were described</li> <li>• P-values provided</li> </ul>	<ul style="list-style-type: none"> <li>• Sample size calculation was not described</li> <li>• Generalizability limited; uncertain as to whether study patients were representative of all patients.</li> </ul>
<b>Economic Evaluations</b>		
Geitona, 2012, Greece <sup>22</sup>	<ul style="list-style-type: none"> <li>• Clearly described purpose of the study</li> <li>• Clearly described research question and specified viewpoint (societal)</li> <li>• Appropriately defined comparators</li> <li>• Provided detailed information on clinical inputs such as effectiveness</li> <li>• Resource use and costs were described</li> <li>• In sensitivity analyses, the range or distribution of values were clearly described</li> </ul>	<ul style="list-style-type: none"> <li>• Time horizon of 1 year was short</li> <li>• Discount rate was not applied</li> <li>• Perspective was not described</li> <li>• The study was conducted using euro cost information from Greece which may limit the generalizability to Canada</li> <li>• Sponsored by manufacturer</li> </ul>
Doran, 2005, Australia <sup>23</sup>	<ul style="list-style-type: none"> <li>• Clearly described research question</li> <li>• Provided detailed information on clinical inputs such as effectiveness</li> <li>• Resource use and costs were described and justified</li> <li>• Perspective was clearly described (a treatment provider perspective)</li> <li>• Appropriately defined comparators</li> <li>• Modeled clinical success</li> <li>• Not sponsored by manufacturer</li> </ul>	<ul style="list-style-type: none"> <li>• Analysis was based on data from a single clinical trial which was conducted almost 10 years ago</li> <li>• Discount rates was not described</li> <li>• Time horizon of 6 months was relatively short</li> <li>• The study was conducted using AUD cost information which may impact its generalizability to Canada</li> </ul>

**APPENDIX 4: Main Study Findings and Authors' Conclusions**

First Author, Publication Year, Country	Main Findings and Authors' Conclusion																				
Randomized controlled trials																					
Neumann, 2013, US <sup>15</sup>	<p><b>Main Findings:</b>  <b>Comparison of SUB versus MET in patients with chronic pain + opioid addiction</b>                      (13 patients in each group completed the study)</p> <table border="1" data-bbox="407 562 1377 716"> <thead> <tr> <th>Outcome</th> <th>SUB</th> <th>MET</th> <th>P value</th> </tr> </thead> <tbody> <tr> <td>Positive urine test for opioids, n (%)</td> <td>5 (38.5)</td> <td>2 (15.4)</td> <td>NS</td> </tr> <tr> <td>Self-reported opioid use, n (%)</td> <td>5 (38.5)</td> <td>0</td> <td>0.039</td> </tr> <tr> <td>Treatment retention, n (%)</td> <td>13 (50.0)</td> <td>13 (46.4)</td> <td>NS</td> </tr> <tr> <td>Self-reported side effects, n (%)</td> <td>8 (61.5)</td> <td>9 (69.2)</td> <td>NS</td> </tr> </tbody> </table> <p><b>Authors' Conclusion:</b>                      After 6 months treatment, no patients in the MET group compared to 5 in the SUB group reported illicit opioid use; other differences between the two groups were not significant.</p>	Outcome	SUB	MET	P value	Positive urine test for opioids, n (%)	5 (38.5)	2 (15.4)	NS	Self-reported opioid use, n (%)	5 (38.5)	0	0.039	Treatment retention, n (%)	13 (50.0)	13 (46.4)	NS	Self-reported side effects, n (%)	8 (61.5)	9 (69.2)	NS
Outcome	SUB	MET	P value																		
Positive urine test for opioids, n (%)	5 (38.5)	2 (15.4)	NS																		
Self-reported opioid use, n (%)	5 (38.5)	0	0.039																		
Treatment retention, n (%)	13 (50.0)	13 (46.4)	NS																		
Self-reported side effects, n (%)	8 (61.5)	9 (69.2)	NS																		
Otiashvili, 2013, Georgia <sup>16</sup>	<p><b>Main Findings:</b>  <b>Comparison of SUB versus MET in adult patients with opioid dependence</b> (at 12 weeks)</p> <table border="1" data-bbox="407 930 1377 1140"> <thead> <tr> <th>Outcome</th> <th>SUB</th> <th>MET</th> <th>P value</th> </tr> </thead> <tbody> <tr> <td>Positive urine test for opioid use, n (%)</td> <td>1 (0.2)</td> <td>6 (1.5)</td> <td>0.03</td> </tr> <tr> <td>Treatment retention, n (%)</td> <td>35 (87.5)</td> <td>33 (82.5)</td> <td>NR</td> </tr> <tr> <td>Adverse events, n</td> <td>108</td> <td>80</td> <td>0.003</td> </tr> </tbody> </table> <p><b>Authors' Conclusion:</b>                      "Daily observed methadone or buprenorphine-naloxone are effective treatments for non-medical buprenorphine and other opioid use in Georgia." P. 1</p>	Outcome	SUB	MET	P value	Positive urine test for opioid use, n (%)	1 (0.2)	6 (1.5)	0.03	Treatment retention, n (%)	35 (87.5)	33 (82.5)	NR	Adverse events, n	108	80	0.003				
Outcome	SUB	MET	P value																		
Positive urine test for opioid use, n (%)	1 (0.2)	6 (1.5)	0.03																		
Treatment retention, n (%)	35 (87.5)	33 (82.5)	NR																		
Adverse events, n	108	80	0.003																		
Saxon, 2013, US <sup>17</sup>  Hser, 2013, US <sup>19</sup> (secondary analysis of Saxon et al.)	<p><b>Main Findings:</b>  <b>Comparison of SUB versus MET in adults with opioid dependence and normal liver function</b></p> <table border="1" data-bbox="407 1329 1279 1633"> <thead> <tr> <th>Outcome</th> <th>SUB</th> <th>MET</th> <th>P value</th> </tr> </thead> <tbody> <tr> <td>Treatment retention, weeks (SD)</td> <td>18.5 (12.7)</td> <td>25.8 (10.0)</td> <td>&lt;0.0001</td> </tr> <tr> <td>Completion rate at 24 weeks, %</td> <td>46.1</td> <td>74.1</td> <td>&lt;0.01</td> </tr> <tr> <td>Serious adverse events, n (%)</td> <td>38 (5.2)</td> <td>45 (8.7)</td> <td>NS</td> </tr> </tbody> </table> <p><b>Authors' Conclusion:</b>                      "MET participants were retained longer in treatment than BUP* participants." P. 71                      * referred to SUB</p>	Outcome	SUB	MET	P value	Treatment retention, weeks (SD)	18.5 (12.7)	25.8 (10.0)	<0.0001	Completion rate at 24 weeks, %	46.1	74.1	<0.01	Serious adverse events, n (%)	38 (5.2)	45 (8.7)	NS				
Outcome	SUB	MET	P value																		
Treatment retention, weeks (SD)	18.5 (12.7)	25.8 (10.0)	<0.0001																		
Completion rate at 24 weeks, %	46.1	74.1	<0.01																		
Serious adverse events, n (%)	38 (5.2)	45 (8.7)	NS																		

First Author, Publication Year, Country	Main Findings and Authors' Conclusion																
Kamien, 2008, US <sup>18</sup>	<p><b>Main Findings:</b> <b>Comparison of SUB versus MET in opioid-dependent patients</b></p> <table border="1"> <thead> <tr> <th data-bbox="407 457 781 485">Outcome</th> <th data-bbox="781 457 943 485">SUB</th> <th data-bbox="943 457 1105 485">MET</th> <th data-bbox="1105 457 1268 485">P value</th> </tr> </thead> <tbody> <tr> <td data-bbox="407 485 781 726">Self-reported days of heroin use in the past days, change from baseline, mean (SE)</td> <td data-bbox="781 485 943 726">Low dose: from 26.9 (0.8) to 5.8 (2.4) High dose: from 26.3 (1.1) to 3.1 (1.7)</td> <td data-bbox="943 485 1105 726">Low dose: from 26.7 (0.8) to 9.0 (2.5) High dose: from 26.3 (0.9) to 4.3 (1.6)</td> <td data-bbox="1105 485 1268 726">=0.05 (low and high doses of study drugs were combined)</td> </tr> <tr> <td data-bbox="407 726 781 863">Treatment retention, weeks (SE)</td> <td data-bbox="781 726 943 863">Low dose: 12.1 (0.2) High dose: 12.5 (0.2)</td> <td data-bbox="943 726 1105 863">Low dose: 13.2 (0.2) High dose: 12.3 (0.2)</td> <td data-bbox="1105 726 1268 863">NR</td> </tr> <tr> <td data-bbox="407 863 781 911">Serious adverse events, n</td> <td data-bbox="781 863 943 911">1</td> <td data-bbox="943 863 1105 911">4</td> <td data-bbox="1105 863 1268 911">NR</td> </tr> </tbody> </table> <p><b>Authors' Conclusion:</b> "Addiction and retention did not differ among groups. Buprenorphine-naloxone is a viable alternative to methadone in clinical practice." P. 5</p>	Outcome	SUB	MET	P value	Self-reported days of heroin use in the past days, change from baseline, mean (SE)	Low dose: from 26.9 (0.8) to 5.8 (2.4) High dose: from 26.3 (1.1) to 3.1 (1.7)	Low dose: from 26.7 (0.8) to 9.0 (2.5) High dose: from 26.3 (0.9) to 4.3 (1.6)	=0.05 (low and high doses of study drugs were combined)	Treatment retention, weeks (SE)	Low dose: 12.1 (0.2) High dose: 12.5 (0.2)	Low dose: 13.2 (0.2) High dose: 12.3 (0.2)	NR	Serious adverse events, n	1	4	NR
Outcome	SUB	MET	P value														
Self-reported days of heroin use in the past days, change from baseline, mean (SE)	Low dose: from 26.9 (0.8) to 5.8 (2.4) High dose: from 26.3 (1.1) to 3.1 (1.7)	Low dose: from 26.7 (0.8) to 9.0 (2.5) High dose: from 26.3 (0.9) to 4.3 (1.6)	=0.05 (low and high doses of study drugs were combined)														
Treatment retention, weeks (SE)	Low dose: 12.1 (0.2) High dose: 12.5 (0.2)	Low dose: 13.2 (0.2) High dose: 12.3 (0.2)	NR														
Serious adverse events, n	1	4	NR														
Non-randomized studies																	
McKeganey, 2013, UK <sup>20</sup>	<p><b>Main Findings:</b></p> <table border="1"> <thead> <tr> <th data-bbox="407 1098 781 1125">Outcome</th> <th data-bbox="781 1098 943 1157">Percentage of patients SUB</th> <th data-bbox="943 1098 1105 1157">Percentage of patients MET</th> <th data-bbox="1105 1098 1268 1125">P value</th> </tr> </thead> <tbody> <tr> <td data-bbox="407 1157 781 1293">Days of heroin use in the past 90 days (change from 6-month timepoint to 14-month timepoint, mean (SD))</td> <td data-bbox="781 1157 943 1293">38.64 (31.05) to 8.5 (12.52)</td> <td data-bbox="943 1157 1105 1293">37.40 (38.66) to 24.15 (33.27)</td> <td data-bbox="1105 1157 1268 1293">NR</td> </tr> <tr> <td data-bbox="407 1293 781 1388">Treatment readiness at 6-month timepoint (score)</td> <td data-bbox="781 1293 943 1388">2.96 (0.35)</td> <td data-bbox="943 1293 1105 1388">3.13 (0.46)</td> <td data-bbox="1105 1293 1268 1388">&lt;0.05</td> </tr> </tbody> </table> <p><b>Authors' Conclusion:</b> "MET and SUB were highly and equally effective for preventing relapse to regular heroin use". P.97</p>	Outcome	Percentage of patients SUB	Percentage of patients MET	P value	Days of heroin use in the past 90 days (change from 6-month timepoint to 14-month timepoint, mean (SD))	38.64 (31.05) to 8.5 (12.52)	37.40 (38.66) to 24.15 (33.27)	NR	Treatment readiness at 6-month timepoint (score)	2.96 (0.35)	3.13 (0.46)	<0.05				
Outcome	Percentage of patients SUB	Percentage of patients MET	P value														
Days of heroin use in the past 90 days (change from 6-month timepoint to 14-month timepoint, mean (SD))	38.64 (31.05) to 8.5 (12.52)	37.40 (38.66) to 24.15 (33.27)	NR														
Treatment readiness at 6-month timepoint (score)	2.96 (0.35)	3.13 (0.46)	<0.05														
Rapeli, 2007, Finland <sup>21</sup>	<p><b>Main Findings:</b> <b>Comparison of SUB versus MET in adult patients</b></p> <table border="1"> <thead> <tr> <th data-bbox="407 1591 651 1619">Outcome</th> <th data-bbox="651 1591 846 1619">SUB</th> <th data-bbox="846 1591 1040 1619">MET</th> <th data-bbox="1040 1591 1349 1619">P value</th> </tr> </thead> <tbody> <tr> <td data-bbox="407 1619 651 1755">Attention (TAP Tonic Alertness, simple reaction time), mean (SD)</td> <td data-bbox="651 1619 846 1755">228 (13)</td> <td data-bbox="846 1619 1040 1755">258 (32)</td> <td data-bbox="1040 1619 1349 1755">NR, favored SUB</td> </tr> <tr> <td data-bbox="407 1755 651 1871">Working memory (WMS-III LNS), mean (SD)</td> <td data-bbox="651 1755 846 1871">8.7 (1.7)</td> <td data-bbox="846 1755 1040 1871">8.8 (2.6)</td> <td data-bbox="1040 1755 1349 1871">NR</td> </tr> </tbody> </table>	Outcome	SUB	MET	P value	Attention (TAP Tonic Alertness, simple reaction time), mean (SD)	228 (13)	258 (32)	NR, favored SUB	Working memory (WMS-III LNS), mean (SD)	8.7 (1.7)	8.8 (2.6)	NR				
Outcome	SUB	MET	P value														
Attention (TAP Tonic Alertness, simple reaction time), mean (SD)	228 (13)	258 (32)	NR, favored SUB														
Working memory (WMS-III LNS), mean (SD)	8.7 (1.7)	8.8 (2.6)	NR														

First Author, Publication Year, Country	Main Findings and Authors' Conclusion
	<p>Verbal memory, 14.8 (0.4) 14.6 (1.0) NR mean (SD)</p> <p><b>Authors' Conclusion:</b> "To preserve cognitive function, the use of SUB may be more preferable to MET use." P. 2</p>
<b>Economic evaluations</b>	
Geitona, 2012, Greece <sup>22</sup>	<p>Retrospective data used for CEA were retrieved from 2 health authority databases. Assessment criteria for outcome assessment: the completion of treatment and number of deaths.</p> <p>CEA (ICER, 2008 euros):</p> <ul style="list-style-type: none"> <li>- Effectiveness: % of treatment completion in SUB was 1.5-fold &gt; than that in MET, % of deaths in SUB was 2.5-fold &lt; than that in MET;</li> <li>- Cost for 1 year: €2,876 for SUB, €5,626 for MET.</li> <li>- ICER: €795.03 for SUB vs. MET for "treatment completion"; €1410.7 for "% of avoided deaths"</li> </ul> <p>Sensitivity analyses: The variation of different individual cost parameters did not reverse the findings of the CEA.</p> <p><b>Author's conclusion:</b> "Analysis of cost effectiveness demonstrated that buprenorphine-naloxone was the dominant therapy in terms of mortality avoidance and completion of treatment." (p. 77)</p>
Doran, 2005, Australia <sup>23</sup>	<p>Data were retrieved from an RCT. Assessment criteria for outcome assessment: changes in the number of heroin-free days between baseline and study end.</p> <p>CEA (ICER, 1998-1999 AUD):</p> <ul style="list-style-type: none"> <li>- Effectiveness: change in number of heroin-free days between baseline and study end was 7.34 days in SUB, and 6.84 days in MET;</li> <li>- Cost for 6 months: AUD1,593 for SUB, AUD1,415 for MET.</li> <li>- ICER: AUD357 (confidence interval: -1,520 to 2,367) for SUB vs. MET for number of heroin-free days between baseline and study end.</li> </ul> <p>Sensitivity analyses: The variation of different individual cost parameters (dosing times, price of BUP and variation in the amount of staff time spent in contact with patients) did not reverse the findings of nonstatistical significance of ICER in the CEA.</p> <p><b>Author's conclusion:</b> "Adopting a provider perspective suggests that the observed difference between the cost-effectiveness of MET and the other treatments was not statistically significant, indicating that high-dose BUP and the BUP/NAL combination can provide a viable alternative to MET in the treatment of heroin dependence." (p. 583)</p>
<p>AUD=Australian dollar; CEA=cost-effectiveness analysis; ICER=incremental cost-effectiveness ratio; MET=metadone; MPD=Memory for Persons Data; NR=not reported; NS = not significant; RCT= randomized controlled trial; SD=standard deviation; SE=standard error of the mean; SUB = Suboxone; TAP=Test for Attentional Performance; WMS-III LNS=Wechsler Memory Scale -3<sup>rd</sup> version</p>	